Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).

Patients in the AsEx group showed a trend toward a shorter median time to first symptom response versus patients in the LtEx group (2.3 months [95% CI, 1.8−3.3] vs 3.8 months [95% CI, 2.6−6.0]; p = .207) even though the difference was not statistically significant, whereas the proportion of patients reaching first symptom response (anytime) was higher in the AsEx group than in the LtEx group (65.5% [114/174 patients] vs 60.6% [80/132 patients]).

also in 53,322 other papers